Understanding Berodual H Aerosol Boehringer Ingelheim
Berodual H Aerosol is a pharmaceutical-grade dual bronchodilator formulation combining ipratropium bromide and fenoterol hydrobromide in a pressurised metered-dose inhaler format. This fixed-dose combination represents a well-established therapeutic approach for respiratory research, offering investigators the opportunity to examine synergistic bronchodilation mechanisms in controlled laboratory settings. The aerosol delivery system allows for precise dosimetry studies and pharmacokinetic evaluation in respiratory research protocols.
Laboratory Applications
Research applications for this Boehringer Ingelheim formulation encompass various aspects of respiratory pharmacology, including bronchodilator mechanism studies, aerosol delivery efficiency investigations, and comparative efficacy evaluations against individual component compounds. Scientists investigating COPD pathophysiology, asthma models, or bronchospasm mechanisms frequently utilise such dual-combination formulations to analyse the complementary effects of anticholinergic and beta-2 agonist pathways. The established clinical profile of this combination makes it valuable for translational research bridging preclinical findings with clinical observations. Our Stroid UK Shop maintains comprehensive documentation for all pharmaceutical-grade compounds. Investigators studying respiratory therapeutics often compare these established formulations with novel compounds from our other drugs category, while some research protocols incorporate metabolic modulators from our SARMs collection or respiratory-related peptides for comprehensive mechanism-of-action studies.
Product Specifications
| Manufacturer | Boehringer Ingelheim |
|---|---|
| Formulation | Pressurised MDI Aerosol |
| SKU | EU21205 |
| Storage Requirements | Room temperature, upright position |
| Research Applications | Respiratory pharmacology, bronchodilator studies |
Research Compliance Statement
This pharmaceutical-grade research material is supplied exclusively for in-vitro laboratory research and analytical applications. Not approved for human consumption, clinical use, or therapeutic applications. Investigators must ensure appropriate research protocols and safety measures are implemented according to institutional guidelines and relevant regulatory frameworks when conducting studies with this bronchodilator combination formulation.
